In January 2025, the U.S. Food and Drug Administration (FDA) approved suzetrigine (brand name: Journavx), a first-in-class non-opioid analgesic developed by Vertex Pharmaceuticals, for the treatment of moderate to severe acute pain in adults. This approval marks the...